Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum

Journal of the American College of Cardiology

Volumn 68, Issue 4, 2016, Pages 368-378

  Opitz, Christian F ^a,b   Hoeper, Marius M ^c   Gibbs, J Simon R ^d   Kaemmerer, Harald ^e   Pepke Zaba, Joanna ^f   Coghlan, J Gerry ^g   Scelsi, Laura ^h   D'Alto, Michele ⁱ   Olsson, Karen M ^c   Ulrich, Silvia ^j   Scholtz, Werner ^k   Schulz, Uwe ^k   Grünig, Ekkehard ^l   Vizza, Carmine D ^m   Staehler, Gerd ⁿ   Bruch, Leonhard ^o   Huscher, Doerte ^p,q   Pittrow, David ^r   Rosenkranz, Stephan ^s  

^a German Red Cross Hospital   (Germany)

^b Medical University of Greifswald   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f PAPWORTH HOSPITAL   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k RUHR UNIVERSITY BOCHUM   (Germany)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ Division of Pneumology Allergology and Sleep Medicine   (Germany)

^o UNFALLKRANKENHAUS BERLIN   (Germany)

^p German Rheumatism Research Centre   (Germany)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^s UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

heart failure with preserved ejection fraction; idiopathic pulmonary arterial hypertension

Indexed keywords

ANTICOAGULANT AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NATRIURETIC FACTOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COMBINED PRE AND POST CAPILLARY PULMONARY HYPERTENSION; COMORBIDITY; CONTROLLED STUDY; DISEASE REGISTRY; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEART INDEX; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MAJOR CLINICAL STUDY; MALE; POST CAPILLARY PULMONARY HYPERTENSION; PRE CAPILLARY PULMONARY HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK ASSESSMENT; SIX MINUTE WALK TEST; TREATMENT RESPONSE; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; EUROPE; FOLLOW UP; HEART CATHETERIZATION; HEART FAILURE; HEART STROKE VOLUME; HYPERTENSION, PULMONARY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE; TRENDS; WALK TEST;

AGED; CARDIAC CATHETERIZATION; EUROPE; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; WALK TEST;

EID: 84990884932     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.047     Document Type: Article

References (29)

1. 1 Lam, C.S.P., Roger, V.L., Rodeheffer, R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009), 1119–1126.
2. 2 Leung, C.C., Moondra, V., Catherwood, E., Andrus, B.W., Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol 106 (2010), 284–286.
3. 3 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circ Heart Fail 7 (2014), 740–751.
4. 4 Mohammed, S.F., Hussain, I., AbouEzzeddine, O.F., et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 130 (2014), 2310–2320.
5. 5 Bursi, F., McNallan, S.M., Redfield, M.M., et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol 59 (2012), 222–231.
6. 6 Melenovsky, V., Hwang, S.-J., Lin, G., Redfield, M.M., Borlaug, B.A., Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35 (2014), 3452–3462.
7. 7 Simonneau, G., Gatzoulis, M.A., Adatia, I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 (2013), D34–D41.
8. 8 Vachiery, J.L., Adir, Y., Barbera, J.A., et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62 (2013), D100–D108.
9. 9 Hoeper, M.M., Bogaard, H.-J., Condliffe, R., et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62 (2013), D42–D50.
10. 10 Galiè, N., Humbert, M., Vachiery, J.L., et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37 (2016), 67–119.
11. 11 Rosenkranz, S., Gibbs, J.S.R., Wachter, R., et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37 (2016), 942–954.
12. 12 Galiè, N., Hoeper, M.M., Humbert, M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30 (2009), 2493–2537.
13. 13 Hoeper, M.M., Huscher, D., Ghofrani, H.A., et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168 (2013), 871–880.
14. 14 Ling, Y., Johnson, M.K., Kiely, D.G., et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 186 (2012), 790–796.
15. 15 Charalampopoulos, A., Howard, L.S., Tzoulaki, I., et al. Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. Pulm Circ 4 (2014), 669–678.
16. 16 Mclaughlin V, Galie N, Barbera JA, et al. A comparison of characteristics and outcomes of patients with atypical and classical pulmonary arterial hypertension from the MAMBITION Trial. Presented at: American Thoracic Society International Conference; May 17, 2015: Denver, CO.
17. 17 Galiè, N., Barberà, J.A., Frost, A.E., et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 373 (2015), 834–844.
18. 18 Olsson, K.M., Delcroix, M., Ghofrani, H.A., et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129 (2014), 57–65.
19. 19 Paulus, W.J., Tschöpe, C., Sanderson, J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550.
20. 20 Hurdman, J., Condliffe, R., Elliot, C.A., et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39 (2012), 945–955.
21. 21 Lewis, G.D., Lachmann, J., Camuso, J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007), 59–66.
22. 22 Lewis, G.D., Systrom, D.M., Semigran, M.J., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007), 1555–1562.
23. 23 Guazzi, M., Vicenzi, M., Arena, R., Guazzi, M.D., PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4 (2011), 8–17.
24. 24 Dumitrescu, D., Seck, C., Möhle, L., et al. Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. Int J Cardiol 154 (2012), 205–206.
25. 25 Guazzi, M., Vicenzi, M., Arena, R., Guazzi, M.D., Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124 (2011), 164–174.
26. 26 Packer, M., McMurray, J., Massie, B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 (2005), 12–20.
27. 27 Redfield, M.M., Chen, H.H., Borlaug, B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309 (2013), 1268–1277.
28. 28 Hoendermis, E.S., Liu, L.C.Y., Hummel, Y.M., et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36 (2015), 2565–2573.
29. 29 Adamson, P.B., Abraham, W.T., Bourge, R.C., et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7 (2014), 935–944.